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http://dx.doi.org/10.1016/j.kjms.201Abstract Hemophilia B (HB) is an X-linked recessive disorder characterized by mutations in
the clotting factor IX (FIX ) gene that result in FIX deficiency. Previous studies have shown a
wide variation of FIX gene mutations in HB. Although the quality of life in HB has greatly
improved mainly because of prophylactic replacement therapy with FIX concentrates, there
exists a significant burden on affected families and the medical care system. Accurate detec-
tion of FIX gene mutations is critical for genetic counseling and disease prevention in HB. In
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188 P.-C. Lin et al.proved to be a highly informative and practical means of detecting mutations, for the molec-
ular diagnosis of our patients with HB. Ten Taiwanese families affected by HB were enrolled.
We used the DHPLC technique followed by direct sequencing of suspected segments to detect
FIX gene mutations. In all, 11 FIX gene mutations (8 point mutations, 2 small deletions/inser-
tions, and 1 large deletion), including two novel mutations (exon6 c.687e695, del 9 mer and
c.460e461, ins T) were found. According to the HB pedigrees, 25% and 75% of our patients
were defined as familial and sporadic HB cases, respectively. We show that DHPLC is a highly
sensitive and cost-effective method for FIX gene analysis and can be used as a convenient sys-
tem for disease prevention.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Hemophilia B (HB) is a congenital bleeding disorder caused
by the deficiency of clotting factor IX (FIX). Patients with
severe HB suffer from frequent hemarthroses and chronic
arthropathy. Although primary prophylaxis with FIX con-
centrates greatly improves the quality of life of patients
with HB, the societal economic burden of the disease re-
mains extremely high. The FIX gene located on the long
arm of chromosome X, Xq27, is 34 kb long and contains
eight exons and seven introns. Most families with HB har-
bor unique FIX mutations, the majority of which are point
mutations; small insertions/deletions as well as larger
deletions have also been identified [1,2]. Following an X-
linked recessive mode of inheritance, patients with HB
typically inherit an FIX gene mutation from their mother
(female carrier). Spontaneous mutations have also been
noted in one-third of the patients with HB with no family
history [3]. A highly sensitive and efficient method for FIX
gene analysis is critical for prenatal diagnosis in affected
families and detection of female carriers [4,5]. Denaturing
high-performance liquid chromatography (DHPLC), which
compares two chromosomes as a mixture of denatured and
reannealed polymerase chain reaction (PCR)-amplified
DNA fragments, offers a rapid and sensitive method for the
detection of gene mutations. By the differential retention
of homo- and heteroduplex DNA, the presence of a muta-
tion can be detected by reversed-phase chromatography.
Point mutations, deletions, and insertions have been
detected successfully by online ultraviolet or fluorescence
monitoring within 2e3 minutes from unpurified amplicons
as large as 1.5 kb [6,7]. In this study, we designed a DHPLC
protocol followed by direct sequencing for the assessment
of 10 amplicons representing the FIX gene promoter re-
gion, coding regions, and exon-flanking sequences. We
validate the use of this approach for the detection of FIX
mutations using a cohort of 10 HB patients and their
families.Figure 1. Algorithm of hemophilia B gene mutation analysis.Methods
Patients
Twelve patients with HB who received replacement therapy
with FIX concentrates in Kaohsiung Medical UniversityHospital (Kaohsiung, Taiwan) and their families were
enrolled in this study. The FIX clotting activity and presence
of FIX inhibitors were tested in each of the individuals
enrolled. Genomic DNA was extracted from whole blood
using the Puregene DNA Isolation Kit (Gentra, Minneapolis,
MN, USA) according to the manufacturer’s instructions. The
algorithm used for FIX gene mutation analysis is shown in
Fig. 1. This study was approved by the Institutional Review
Board of Kaohsiung Medical University Hospital (Kaohsiung,
Taiwan).
Assay design and PCR conditions
Primers for all 10 amplicons are listed in Table 1. The sizes
of the amplicons used were approximately 400e600 bp.
Each PCR reaction was carried out in a mixture containing
the following reagents: 2.5 mL of 10 buffer, 2 mL of 2.5 mM
MgCl2, 1 mL of 2.5 mM dNTP, 0.3 mL each of 10 mM forward
and reverse primers, 0.1 mL of 5 U/mL Taq DNA polymerase,
and 2 mL of 50 ng/mL DNA. The final volume of PCR reactions
was 25 mL. Thermocycler conditions used for PCR were as
follows: a denaturationeactivation step at 95C for 10 mi-
nutes, followed by a 14-cycle program (denaturation at
95C for 30 seconds, annealing at 57C for 30 seconds, and
elongation at 72C for 45 seconds), and a 26-cycle program
(denaturation at 95C for 30 seconds, annealing at 50C for
Table 1 HB Primer pairs and PCR conditions for DHPLC analysis.






HB promoter Fa ACAAGCTACAGGCTGGAGACA 410 57 53 57e66 53e62
HB promoter Rb CAAAGACCATTGAGGGAGA
HB e1 F CCCATTCTCTTCACTTGTCC 407 60 57 56 57e66 56e65
HB e1 R CCTAGCTAACAAAGAACCAGT
HB e2þ3 F AGAGATGTAAAATTTTCATGATGTT 506 64 59 55 59e68 54e63
HB e2þ3 R GCAGAGAAAAAACCCACATAAT
HB e4 F CTGCAGGGGAGGACCGGGCATTCTA 245 64 51 49 51e60 49e58
HB e4 R GAATTCAACTTGTTTCAGAGGGAA
HB e5 F CATGAGTCAGTAGTTCCATGTACTTT 272 62 53 51 53e62 51e60
HB e5 R TGTAGGTTTGTTAAAATGCTGAAGTT
HB e6 F TTTAAATACTGATGGGCCTG 458 57 58 56 58e67 56e65
HB e6 R GTTAGTGCTGAAACTTGCCT
HB e7 F AAGCTCACATTTCCAGAAAC 393 56 57 57e66
HB e7 R TGGGTTCTGAAATTATGA
HB e8-1 F TAAGAATGAGATCTTTAACA 394 51 55 57 57e66 55e64
HB e8-1 R CTAAGGTACTGAAGAACTAA
HB e8-2 F GAAGAGTCTTCCACAAAGGG 391 59 55 57 55e64 57e66
HB e8-2 R AAGATGGGAAAGTGATTAGTTA
HB poly A F AAGAGAACCGTTCGTTTGCA 521 59 59 59e68
HB poly A R AGAACTAAAGGAACTAGCAAG
DHPLC Z denaturing high-performance liquid chromatography; HB Z hemophilia B; PCR Z polymerase chain reaction.
a F Z forward.
b R Z reverse.
Novel FIX mutations in hemophilia B by DHPLC 18930 seconds, elongation at 72C for 45 seconds, and a final
elongation at 72C for 10 minutes).
DHPLC
Equal volumes of the amplified PCR products from a patient
and a wild-type (male) control were mixed, denatured at
95C for 5 minutes, and then incubated at 65C for 30 mi-
nutes to obtain heteroduplexes. Mutational screening,
performed for all amplified fragments from each patient,
was carried out by DHPLC on a Wave DNA Fragment Analysis
System (Transgenomic Inc., San Jose, CA, USA) using a
DNASep column (Transgenomic Inc.). DNA molecules eluted
from the column were detected by scanning with a UV
detector at 260 nm. For DHPLC analysis, heterozygous
profiles were identified by visual inspection of the
chromatograms.
Direct sequencing
Direct DNA sequencing was performed on samples showing
an abnormal peak pattern. The sequencing process was
carried out in a final volume of 10 mL of the purified PCR
products, 2.5mM of one of the PCR primers, and 1 mL of ABI
PRISM Terminator v3.1 Cycle Sequencing Kit (Applied Bio-
systems, Foster City, CA, USA). A 25-cycle PCR program
with denaturation at 96C for 10 seconds, annealing at 50C
for 5 seconds, and elongation at 60C for 4 minutes was
conducted in an ABI PRISM 310 Genetic Analyzer (Applied
Biosystems). Each mutation was confirmed on a second,
independent, amplified PCR sample. In order to rule out the
possibility of exonic polymorphisms, 150 DNA samples fromhealthy, unrelated controls were screened and found
negative for the novel missense mutations.
Results
Ten families, including 15 individuals (12 patients with HB
and 3 female carriers), were enrolled in this study. Prior to
this study, all 12 patients and one of the female carriers
(Case No. 5) had received FIX concentrates replacement
therapy in our hospital (on demand or as prophylaxis), and
no evidence of FIX inhibitors had been found. FIX gene
mutations were detected by DHPLC and subsequent DNA
sequencing of suspected segments in all patients and fe-
male carriers. In all, 11 FIX gene mutations were detected
(Table 2), including eight point mutations (2 nonsense
mutations and 6 missense mutations), one small deletion
(Family No. 2), one small insertion (Family No. 6), and one
large deletion (Family No. 8). Nine of the 11 identified FIX
mutations were listed in the HB Mutation Database (version
13, 2004), and their respective references are listed in
Table 2 [8e14]. Two mutations (exon6: c.687_695, del 9
mer and c460_461, ins T) were determined to be novel
mutations after a search of literature published between
2004 and 2012 [15e23]; both of these mutations resulted in
severe FIX deficiency in men (Cases No. 4 and No. 11).
Discussion
Thus far, heterogeneous FIX gene mutations have been
identified in all HB patients reported, and the majority of
these are point mutations. For example, among 2891







FIX gene mutations Reference
Position Nucleotide Amino acid
1 1 Severe 0.7 17701 Exon5: c.424, G > T,
GAG > TAG
p.Glu142* [8]
1 2 Female carriera 25.0 17701 Exon5: c.424, G > T,
GAG > TAG IX gene WT
p.Glu142*/F [8]
1 3 Female carrierb 29.0 17701 Exon5: c.424, G > T,
GAG > TAG IX gene WT
p.Glu142*/F [8]
2 4 Severe 0.1 20529e20537 FIX gene exon6: c.687_695,
del 9 mer (TGGAGAAGA)
In-frame shift Novel
2 5 Female carrierc 28.0 20529e20537 FIX gene exon6: c.687_695,
del 9 mer (TGGAGAAGA)
In-frame shift Novel
3 6 Moderate 1.4 30098 Exon7: c.783, G > T,
TGG > TGT
p.Trp261Cys [9]
3 7 Severe 0.6 30098 Exon7: c.783, G > T,
TGG > TGT
p.Trp261Cys [9]
3 8 Severe 0.8 30098 Exon7: c.783, G > T,
TGG > TGT
p.Trp261Cys [9]
4 9 Severe 0.4 20554 Exon6: c.712, T > G,
TTC > GTC
p.Phe238Val [10]
31307 Exon8: c.1324, G > A,
GGA > AGA
p.Gly442Arg [11]
5 10 Severe 0.6 10391 c.277, G > A, GAT > AAT p.Asp93Asn [12]
6 11 Severe 0.3 17737e17738 c.460_461, ins T Novel
7 12 Moderate 2.0 10403 c.289, T > C, TGT > CGT p.Cys97Arg [13]
8 13 Severe 0.8 del 9900e19218 Exon4eexon5 deletion [14]
9 14 Severe 0.9 6460 c.223, C > T, CGA > TGA p.Arg75* [9]
10 15 Severe 0.6 31216 c.1233, T > G, AGT > AGG p.Ser411Arg [10, 12]
a Mother of Case No. 1.
b Sister of Case No. 1.









Figure 2. Sequences of two novel FIX gene mutations. (A)
Segments containing putative mutations of Case No. 5 (female
carrier) revealed to be heterozygous for exon6 c.687e695, del
9 mer and wild type. (B) Homozygous c.460e461, ins T in Case
No. 11.
Novel FIX mutations in hemophilia B by DHPLC 191patient entries in the HB Mutation Database version 13, only
91 patients have gross deletions/insertions and 211 have
short deletions/insertions (defined as less than 30 nucleo-
tides). In addition, nearly one-third of the patients listed in
the database carry unique mutations, 34 patients carry
double mutations, and one patient has been described to
carry triple FIX mutations. Therefore, complete FIX gene
screening is mandatory during genetic counseling for HB.Direct sequencing is the most sensitive method for
detecting gene mutations; however, it is expensive and
time consuming, thereby making it less suitable for genetic
screening tests. Conventional screening methods such as
single-stranded conformational polymorphisms, conforma-
tional sensitive gel electrophoresis, and chemical mismatch
cleavage have also been used for FIX gene analysis, but
these techniques only have 70e80% sensitivity [24,25].
DHPLC, developed by Professor Oefner and colleagues
[26e28], allows the automated detection of single-base
substitutions as well as small insertions and deletions.
DHPLC has been applied to detect mutations for various
diseases and has proved to have higher sensitivity and
specificity (over 90%) than conventional screening methods
[7,28e30].
In our study, we successfully used DHPLC and subsequent
DNA sequencing of suspected segments to detect FIX gene
mutations, including point mutations, small deletions/in-
sertions, and a gross deletion in all the HB patients and
female carriers screened. We were also able to confirm the
presence of double point mutations in one of our patients.
In addition, we identified two novel FIX gene mutations
(Fig. 2). The first of these was a small deletion of nine
nucleotides (nucleotides 20529e20537), which is predicted
to result in an in-frame mutation (Gly183eGly184e-
Glu185eAsp186eAla187 > Gly183eAla184) involving the
catalytic domain (Fig. 3A). Because this region is near the
activated FIX (FXIa) cleavage site (Arg180eVal181), which is
critical for the formation of FIXa as well as the specificity of
the catalytic domain for binding to factor VIIIa, this muta-
tion is expected to influence FIX activation or subsequent
FVIIIa binding, resulting in severe HB. The second novel
mutation identified was a single nucleotide insertion be-
tween 17,737 bp and 17,738 bp, and it is predicted to result
in a premature stop codon (Fig. 3B). Both of these muta-
tions were associated with an FIX activity of less than 1%,
and no FIX inhibitor was observed in either patient.
Familial cases were defined in this study as patients with
relatives (belonging to an earlier generation) or an older
cousin who were either affected with or carrying HB [31].
According to the pedigrees used in our study cohort, only
Cases No. 6, No. 7, and No. 8 were defined as familial (Case
No. 6 was an older cousin of Cases No. 7 and No. 8). Case
No. 1 had a sibling who was proved to be a female carrier
(Case No. 3), and this pair was thus defined as a sporadic
sibship (first affected sibship). The other patients were
determined to be sporadic isolated cases. Collectively, 25%
of the HB patients were clearly familial, and 75% were
sporadic (mostly sporadic isolated cases). The prevalence
of familial HB cases varied widely in previous studiesdfrom
15% (2/14) in the study by Bicocchi et al. [32] to 57% (82/
144) in the study by Kasper and Lin [31]. Our data were
more similar to those reported by Bicocchi et al. [32] than
to those reported by Kasper and Lin [31]. Because the co-
horts used in both this study and the study by Bicocchi et al.
[32] were small, we suspect that the prevalence of familial
HB cases observed was influenced by sample size.
In conclusion, we found that DHPLC could efficiently
detect all forms of FIX gene mutations in HB patients and
female carriers and also identify novel mutations. Thus,
DHPLC can be used as a cost-effective and sensitive method
for confirmation of HB cases as well as for carrier diagnosis.
Figure 3. Nucleotides and amino acid sequences of the wild-type and two novel mutant FIX genes. (A) Nucleotide positions
20518e20538 of the wild-type FIX gene and 20529e20537 deletion (exon6 c.687e695, del 9 mer). The deleted nucleotides and the
predicted mutated sequence are shown as red and green letters, respectively. (B) Nucleotide positions 17735e17758 of the wild-
type FIX gene and 17737e17738 insT (c.460e461, ins T). The insert T is indicated in red, and the predicted amino acids are shown as
green letters.
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